JF
KLRS

Jump Financial’s Kalaris Therapeutics KLRS Stock Holding History

Jump Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-633
Closed -$10.5K – 2207
2024
Q2 		$10.5K Buy
+633
New +$11.2K ﹤0.01% 1728
2023
Q4 		– Sell
-1,582
Closed -$78.3K – 2338
2023
Q3 		$78.3K Buy
+1,582
New +$108K ﹤0.01% 1708
2023
Q1 		– Sell
-1,624
Closed -$192K – 2133
2022
Q4 		$192K Buy
+1,624
New +$275K 0.01% 1305
2022
Q3 		– Sell
-583
Closed -$52K – 2051
2022
Q2 		$52K Sell
583
-678
-54% -$71.1K ﹤0.01% 1501
2022
Q1 		$196K Buy
+1,261
New +$252K 0.01% 1316
2021
Q4 		– Sell
-662
Closed -$381K – 1785
2021
Q3 		$381K Buy
+662
New +$307K 0.03% 565
2021
Q2 		– Sell
-652
Closed -$351K – 1442
2021
Q1 		$351K Buy
+652
New +$548K 0.03% 551

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Jump Financial's KLRS Position: Q3 2024 in Review

Jump Financial sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 633 shares — an estimated $10.5K sold.

Jump Financial first reported a position in KLRS in Q1 2021 and held it in 7 quarters. The position peaked at $381K in Q3 2021. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Jump Financial reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jump Financial sold 633 Kalaris Therapeutics shares in Q3 2024, an estimated $10.5K.
  • Jump Financial first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 7 quarters.
  • Jump Financial's Kalaris Therapeutics position peaked at $381K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Jump Financial's 13F filing for Q3 2024, filed 14 Nov 2024.